Moderate activation of the apoptosis inhibitor bcl-xL worsens the prognosis in pancreatic cancer

Annals of Surgery

Volumn 228, Issue 6, 1998, Pages 780-787

  Friess, Helmut ^a   Lu, Zhao ^a   Andrén Sandberg, Åke ^a   Berberat, Pascal ^a   Zimmermann, Arthur ^b   Adler, Guido ^c   Schmid, Roland ^c   Büchler, Markus W ^a  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BERN   (Switzerland)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN BCL X;

ADULT; AGED; APOPTOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CONFERENCE PAPER; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; PROGNOSIS;

ADULT; AGED; APOPTOSIS; BCL-X PROTEIN; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SURVIVAL RATE;

EID: 0032471711     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199812000-00009     Document Type: Conference Paper

References (51)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics. 1997. Ca 1997;47:5-27.
2. Baer HU, Wagner M, Büchler MW. Pancreatic cancer: indications for surgery. Dig Surg 1994; 11:372-377.
3. Beger HG, Büchler MW, Friess H. Surgical results and indications for adjuvant measures in pancreatic cancer. Chirurg 1994; 65:246-252.
4. Ihse I, Anderson H, Andren-Sandberg A. Total pancreatectomy for cancer of the pancreas: is it appropriate? World J Surg 1996; 20:288-293.
5. Guo XZ, Friess H, Graber HU, et al. Kail expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. Cancer Res 1996; 56:4876-4880.
6. Büchler M, Friess H, Schultheiss KH. et al. A randomized controlled trial of adjuvant immunotherapy (murine monoclonal antibody 494/ 32) in resectable pancreatic cancer. Cancer 1991; 68:1507-1512.
7. Friess H, Büchler M, Krüger M, Beger HG. Treatment of duct carcinoma of the pancreas with the LH-RH-analogue buserelin. Pancreas 1992; 7:516-521.
8. Andren-Sandberg A, Bäckman PL, Andersson R. Results of adjuvant therapy in resected pancreatic cancer. Int J Pancreatol 1997; 21:31-38.
9. Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, Leonard RC. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81:882-885.
10. Miyashita T, Reed JC. Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 1993; 81:151-157.
11. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80:879-886.
12. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol 1994; 124:1-6.
13. Reed JC, Miyashita T, Takayama S, et al. Bcl-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy. J Cell Biochem 1996; 60:23-32.
14. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell 1993; 74:609-619.
15. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Oltvai ZN. Bcl-2/Bax: a rheostat that regulates and anti-oxidant pathway and cell death. Cancer Biol 1993; 4:327-332.
16. McDonnell TJ, Deane N, Platt FM, et al. Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 1989; 57:79-88.
17. Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. Blood 1992; 80:879-886.
18. McDonnell TJ, Beham A, Sarkiss M, Andersen MM, Lo P. Importance of the Bcl-2 family in cell death regulation. Experientia 1996; 52: 1008-1017.
19. Cleary ML, Smith SD, Sklar J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14;18) translocation. Cell 1986; 47:19-28.
20. Seto M, Jaeger U, Hockett RD, et al. Alternative promoters and exons, somatic mutation and deregulation of the Bcl-2-Ig fusion gene in lymphoma. EMBO J 1988; 7:123-131.
21. Strasser A, Harris AW, Cory S. bcl-2 transgene inhibits T cell death and perturbs thymic self-censorship. Cell 1991; 67:889-899.
22. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, Korsmeyer SJ. Bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991; 67:879-888.
23. Boise LH, Gonzalez-Garcia M, Postema CE, et al. Bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death. Cell 1993; 74:597-608.
24. Hermanek P, Sobin LH. TNM classification of malignant tumor, 4th ed. Union International Contre Cancer, Geneva/New York: Springer-Verlag, 1992:71-73.
25. Friess H, Yamanaka Y, Büchler M, et al. Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. Cancer Res 1993; 53:2704-2707.
26. Friess H, Yamanaka Y, Büchler M, et al. Enhanced expression of transforming growth factor β isoforms in pancreatic cancer correlates with decreased survival. Gastroenterology 1993; 105:1846-1856.
27. Lu Z, Friess H, Graber H, et al. The presence of two signaling TGF-β receptors in human pancreatic cancer correlates with advanced tumor stage. Dig Dis Sci 1997; 42:2054-2063.
28. Friess H, Cantero D, Graber H, et al. Enhanced urokinase plasminogen activation in chronic pancreatitis suggests a role in its pathogenesis. Gastroenterology 1997; 113:904-913.
29. Riesle E, Friess H, Zhao L, et al. Increased expression of transforming growth factor betas after acute oedematous pancreatitis in rats suggests a role in pancreatic repair. Gut 1997; 40:73-79.
30. Gress TM, Muller-Pillasch F, Lerch MM, Friess H, Büchler M, Adler G. Expression and in situ localization of genes coding for extracellular matrix proteins and extracellular matrix degrading proteases in pancreatic cancer. Int J Cancer 1995; 62:407-413.
31. Siegel S. Nonparametric statistics for behavioral science. New York: McGraw-Hill, 1956.
32. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. Bad, a heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80:285-291.
33. O'Reilly LA, Huang DC, Strasser A. The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J 1996; 15:6979-6990.
34. Huang DC, O'Reilly LA, Strasser A, Cory S. The anti-apoptosis function of Bcl-2 can be genetically separated from its inhibitory effect on cell cycle entry. EMBO J 1997; 16:4628-4638.
35. Cheng EH, Levine B, Boise LH, Thompson CB, Hardwick JM. Bax-independent inhibition of apoptosis by Bcl-xL. Nature 1996; 370:554-556.
36. Gottschalk AR, Boise LH, Thompson CB, Quintans J. Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2. Proc Natl Acad Sci USA 1994; 91:7350-7354.
37. Gauthier ER, Piche L, Lemieux G, Lemieux R. Role of bcl-x(L) in the control of apoptosis in murine myeloma cells. Cancer Res 1996: 56:1451-1456.
38. Krajewski S, Krajwaska M, Shabaik A, et al. Immunohistochemical analysis of in vivo patterns of bcl-x expression. Cancer Res 1994; 54:5501-5507.
39. Offit K, Wong G, Filippa DA, Tao Y, Chaganti RS. Cytogenetic analysis of 434 consecutively ascertained specimens of non-Hodgkin's lymphoma: clinical correlations. Blood 1991; 77:1508-1515.
40. Yunis JJ, Mayer MG, Arensen MA, Aeppli DP, Oken MM, Frizzera G. Bcl-2 and other genomic alterations in the prognosis of large-cell lymphomas. N Engl J Med 1989; 320:1047-1054.
41. Schott AF, Apel IJ, Nunez G, Clarke MF. Bcl-xL protects cancer cells from p53-mediated apoptosis. Oncogene 1995; 11:1389-1394.
42. Kondo S, Shinomura Y, Kanayama S, et al. Over-expression of bcl-xl gene in human gastric adenomas and carcinomas. Int J Cancer 1996; 68:727-730.
43. Krajewska M, Moss SF, Krajewski S, Song K, Holt PR, Reed JC. Elevated expression of bcl-x and reduced bak in primary colorectal adenocarcinomas. Cancer Res 1996; 56:2422-2427.
44. Dole MG, Jasty R, Cooper MJ, Thompson CB, Nunez G, Castle VP. Bcl-xL is expressed in neuroblastoma cells and modulates chemotherapy-induced apoptosis. Cancer Res 1995; 55:2576-2582.
45. Foreman KE, Wrone-Smith T, Boise LH, et al. Kaposi's sarcoma tumor cells preferentially express bcl-xL. Am J Pathol 1996; 149:795-803.
46. Datta R, Manome Y, Taneja N, et al. Overexpression of Bcl-xL by cytotoxic drug exposure confers resistance to ionizing radiation-induced internucleosomal DNA fragmentation. Cell Growth Differ 1995; 6:363-370.
47. Cherbonnel-Lasserre C, Gauny S, Kronenberg A. Suppression of apoptosis by Bcl-2 or Bcl-xL promotes susceptibility to mutagenesis. Oncogene 1996; 13:1489-1497.
48. Deflorin J, Friess H, Schmid R, et al. Überexpression von Apoptosis-genen beim humanen Pankreaskarzinom. Swiss Surgery 1995; (Suppl 2):17.
49. Friess H, Berberat P, Schilling M, Kunz J, Korc M, Büchler MW. Pancreatic cancer: the potential clinical relevance of alterations in growth factors and their receptors. J Mol Med 1996; 74:35-42.
50. Berthelemy P, Bouisson M, Escourrou J, Vaysse N, Rumeau JL, Pradayrol L. Identification of K-ras mutations in pancreatic juice in the early diagnosis of pancreatic cancer. Ann Intern Med 1995; 123:188-191.
51. Cantero D, Friess H, Deflorin J, et al. Enhanced expression of urokinase plasminogen activator and its receptor in pancreatic carcinoma. Br J Cancer 1997; 75:388-395.